Table 3.
Sensitivity Analysis
| Statistical index (rate) | No. of included study | Statistical method | RR (95% CI) | p-value |
|---|---|---|---|---|
| Short-term clinical remission | 3 | Fixed | 1.50 (1.08–2.09) | 0.0200 |
| Random | 1.50 (1.08–2.09) | 0.0200 | ||
| Short-term clinical response | 3 | Fixed | 1.33 (1.16–1.52) | <0.0001 |
| Random | 1.32 (1.15–1.52) | <0.0001 | ||
| Short-term mucosal healing | 3 | Fixed | 1.21 (1.04–1.41) | 0.0200 |
| Random | 1.20 (1.00–1.44) | 0.0500 | ||
| Short-term IBDQ response | 2 | Fixed | 1.23 (1.06–1.43) | 0.0060 |
| Random | 1.24 (1.07–1.44) | 0.0050 | ||
| Long-term clinical remission | 2 | Fixed | 2.38 (1.57–3.59) | <0.0001 |
| Random | 2.32 (1.53–3.50) | <0.0001 | ||
| Long-term clinical response | 2 | Fixed | 1.69 (1.69–2.21) | 0.0001 |
| Random | 1.68 (1.29–2.21) | 0.0002 | ||
| Long-term mucosal healing | 2 | Fixed | 1.69 (1.26–2.28) | 0.0005 |
| Random | 1.69 (1.25–2.28) | 0.0006 | ||
| Long-term IBDQ response | 2 | Fixed | 1.73 (1.28–2.34) | 0.0004 |
| Random | 1.71 (1.27–2.32) | 0.0005 | ||
| Long-term steroid-free remission | 2 | Fixed | 2.22 (1.19–4.17) | 0.0100 |
| Random | 2.23 (1.19–4.18) | 0.0100 | ||
| Short-term clinical remission, 160/80 mg 0/2 wk | 3 | Fixed | 1.62 (1.15–2.29) | 0.0060 |
| Random | 1.58 (1.05–2.40) | 0.0300 | ||
| Short-term clinical response, 160/80 mg 0/2 wk | 3 | Fixed | 1.37 (1.19–1.59) | <0.0001 |
| Random | 1.36 (1.18–1.58) | <0.0001 | ||
| Short-term mucosal healing, 160/80 mg 0/2 wk | 3 | Fixed | 1.27 (1.08–1.50) | 0.0004 |
| Random | 1.26 (1.08–1.49) | 0.0005 | ||
| Short-term clinical remission, 80/40 mg 0/2 wk | 2 | Fixed | 1.14 (0.67–1.94) | 0.6300 |
| Random | 1.14 (0.67–1.95) | 0.6300 | ||
| Short-term clinical response, 80/40 mg 0/2 wk | 2 | Fixed | 1.17 (0.95–1.44) | 0.1400 |
| Random | 1.17 (0.95–1.44) | 0.1400 | ||
| Short-term mucosal healing, 80/40 mg 0/2 wk | 2 | Fixed | 1.04 (0.82–1.32) | 0.7600 |
| Random | 1.06 (0.75–1.49) | 0.7600 | ||
| Long-term clinical remission, 160/80 mg 0/2 wk | 2 | Fixed | 2.20 (1.45–3.36) | 0.0002 |
| Random | 2.20 (1.44–3.35) | 0.0003 | ||
| Short-term clinical remission (baseline CS) | 2 | Fixed | 1.10 (0.65–1.86) | 0.7200 |
| Random | 1.07 (0.49–2.35) | 0.8600 | ||
| Short-term clinical remission (baseline no CS) | 2 | Fixed | 1.86 (0.75–4.64) | 0.1800 |
| Random | 1.75 (0.69–4.43) | 0.2400 | ||
| Short-term clinical remission (baseline IMM) | 2 | Fixed | 4.51 (1.40–14.51) | 0.0100 |
| Random | 4.39 (1.35–14.21) | 0.0100 | ||
| Short-term clinical remission (baseline no IMM) | 2 | Fixed | 0.81 (0.49–1.35) | 0.4200 |
| Random | 0.76 (0.34–1.73) | 0.5200 | ||
| Adverse event | 2 | Fixed | 1.02 (0.94–1.10) | 0.6800 |
| Random | 1.00 (0.93–1.07) | 0.9700 | ||
| Serious adverse event | 2 | Fixed | 1.09 (0.78–1.53) | 0.6100 |
| Random | 1.09 (0.78–1.53) | 0.6000 | ||
| Injection-site reaction | 2 | Fixed | 2.52 (1.48–4.28) | 0.0006 |
| Random | 2.51 (1.47–4.29) | 0.0007 |
RR, relative risk; IBDQ, inflammatory bowel disease questionnaire; CS, corticosteroid; IMM, immunomodulators.